source
- STAT podcast highlights investor buzz around hair loss drugs, AI in trials, and Servier's M&A ambitionsThe latest episode of STAT’s “The Readout LOUD” podcast explored why investors are increasingly focused on treatments for hair loss, noting recent trial data that has generated notable market inter…
- Akeso‑Summit’s ivonescimab lands a prime ASCO plenary slot despite unclear survival dataThe upcoming American Society of Clinical Oncology meeting will feature a plenary presentation from Akeso and Summit Therapeutics on their lung‑cancer candidate ivodescimab. Industry observers note…